
    
      This is a multicenter (when more than one hospital or medical school team work on a medical
      research study), prospective (study following participants forward in time), open-label (all
      people know the identity of the intervention) study of infliximab in pediatric participants
      with inflammatory bowel disease. The study consists of 3 Phases: screening Phase (up to 4
      weeks), open-label treatment Phase (56 weeks) and follow up safety Phase (8 weeks). The
      duration of participation in the study for each participant is approximately up to 68 weeks
      (including screening period). Participants' efficacy and safety outcomes will be monitored
      throughout the study.
    
  